KR0155231B1 - Proteoglycan extracted from artemisza swa yomogi and their preparation method - Google Patents
Proteoglycan extracted from artemisza swa yomogi and their preparation methodInfo
- Publication number
- KR0155231B1 KR0155231B1 KR1019950023493A KR19950023493A KR0155231B1 KR 0155231 B1 KR0155231 B1 KR 0155231B1 KR 1019950023493 A KR1019950023493 A KR 1019950023493A KR 19950023493 A KR19950023493 A KR 19950023493A KR 0155231 B1 KR0155231 B1 KR 0155231B1
- Authority
- KR
- South Korea
- Prior art keywords
- polysaccharide
- mugwort
- protein polysaccharide
- artemisza
- yomogi
- Prior art date
Links
- 235000017519 Artemisia princeps Nutrition 0.000 title 1
- 244000065027 Artemisia princeps Species 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 23
- 239000005017 polysaccharide Substances 0.000 claims abstract description 23
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 22
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 22
- 150000004676 glycans Chemical class 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 6
- 208000019423 liver disease Diseases 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 235000003826 Artemisia Nutrition 0.000 claims abstract description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000009052 artemisia Nutrition 0.000 claims abstract description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000008103 glucose Substances 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- NTKNGUAZSFAKEE-UHFFFAOYSA-N capillarisin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1OC1=CC=C(O)C=C1 NTKNGUAZSFAKEE-UHFFFAOYSA-N 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 241000092666 Artemisia iwayomogi Species 0.000 description 1
- 235000007806 Artemisia iwayomogi Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000010815 organic waste Substances 0.000 description 1
- -1 phosphorus polysaccharide Chemical class 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
본 발명에 의하여 인진쑥(Artemisia swayomogi)으로부터 분리하여 얻어진 단백 다당체는 간질환의 치료 및 예방효과가 탁월하며 글루코오스(glucose) 71.2%, 자일로오스(xylose) 25.4%, 만노오스(mannose) 2.8%, 람노오스(rhamnose) 0.6%(몰%)를 함유하며 질소를 1.4% 함유하고 단백은 다음의 아미노산으로 구성되어 있다.Protein polysaccharide obtained by separating from Artemisia swayomogi according to the present invention is excellent in the treatment and prevention of liver disease, glucose 71.2%, xylose 25.4%, mannose 2.8%, rhamno It contains 0.6% (mol%) of rhamnose, 1.4% of nitrogen, and the protein consists of the following amino acids.
Description
제1도는 인진쑥 단백 다당체의 최종분획(KP)의 자외-가시 분광 스펙트럼이며,FIG. 1 is an ultraviolet-visible spectral spectrum of the final fraction (KP) of phospholipid protein polysaccharides
제2도는 인진쑥 단백 다당체의 최종분획(KP)의 적외선 분광 스펙트럼이며,FIG. 2 is an infrared spectral spectrum of the final fraction (KP) of phospholipid protein polysaccharide.
제3도는 인진쑥 단백 다당체의 최종분획(KP)의 아미노산 분석 크로마토그램이다.FIG. 3 is an amino acid analysis chromatogram of the final fraction (KP) of phospholipid protein polysaccharide.
[발명의 목적][Purpose of invention]
본 발명은 간세포 재생효과 및 간염 치료효과가 우수한 인진쑥 단백 다당체의 추출 및 정제에 관한 것이다.The present invention relates to the extraction and purification of the erythroid protein polysaccharide excellent in hepatocyte regeneration effect and hepatitis treatment effect.
인진쑥(학명:Artemisia iwayomogi)은 인진, 인진호, 더위지기 또는 사철쑥이라고도 불리워지며 우리나라의 각처에 자생하고 있는 자원이 매우 풍부한 식물자원이다.Injin mugwort (Artemisia iwayomogi) is also called injin, injinho, heat keeper or evergreen mugwort, and is a very rich plant resource native to all parts of Korea.
인진쑥은 자원이 풍부할 뿐만 아니라, 민간요법에서 간염, 간암, 간경변등의 각종의 간질환에 빈번히 사용되고 있는 국화과의 식물이다. 우리나라에는 음주인구가 많고 각종의 간장 관련 질환이 국가적 문제로 대두되어 있으므로 인진쑥으로써 간기능개선효과가 우수한 단백 다당체 분획을 분리정제하는 것이 본 발명의 목적이다.Injin mugwort is not only rich in resources, but is also a plant of the Asteraceae, which is frequently used for various liver diseases such as hepatitis, liver cancer, and cirrhosis in folk medicine. In Korea, since there are many drinking populations and various liver-related diseases have emerged as a national problem, it is an object of the present invention to separate and purify protein polysaccharide fractions having excellent liver function improvement effect as a jinjin mugwort.
[종래기술 및 그 문제점][Prior Art and Problems]
인진쑥을 간장 질환에 사용하는 종래의 기술은 주로 유기용매를 이용하여 capillarisin, scoparon 등의 유효성분을 추출하여 crude한 상태로 제조하는 것이다(JP 90142781).The conventional technique of using jinjin mugwort in liver disease is mainly to extract the active ingredients such as capillarisin, scoparon, etc. using an organic solvent to produce a crude state (JP 90142781).
그러나 유기용매를 사용할 경우 최종 product에 소량의 유기용매가 잔존할 가능성이 높기 때문에 인체에 유해할 수 있으며 유기 폐액의 폐기에 있어서도 심각한 환경 공해를 일으킬 수 있다.However, when organic solvents are used, a small amount of organic solvents may remain in the final product, which may be harmful to the human body, and may cause serious environmental pollution even in the disposal of organic waste liquids.
한편, 인진쑥을 물로 추출하여 세파덱스로 인진쑥 단백 다당체를 정제하는 것과 관련된 특허는 아직 없다.On the other hand, there are no patents related to the purification of Injin mugwort protein polysaccharides with Sephadex by extracting Injin mugwort with water.
[발명의 구성, 작용 및 효과][Configuration, Action and Effect of the Invention]
본 발명은 인진쑥을 물로 추출하여 추출액을 정제한 후 이의 구성성분을 규명하여 이가 단백 다당체임을 규명하였으며, 이 단백 다당체는 우수한 간장보호기능을 가진다. 본 발명을 설명하면 다음과 같다.The present invention was purified by extracting Injin mugwort with water to determine the constituents of the extract to determine that it is a protein polysaccharide, this protein polysaccharide has excellent hepatoprotective function. When explaining the present invention.
인진쑥을 곱게 세절한 후 40-100℃, pH 3-8의 물로 4-12시간 2-3회 추출한 후 여과한다.Finely chopped Injin mugwort and extract 2-3 times with water of 40-100 ° C. and pH 3-8 for 2-3 hours, followed by filtration.
여과액을 감압농축한 후 과량의 수용성 알코올(메탄올, 에탄올, 부탄올 등 C1-C5까지의 지방족 알코올을 의미함)을 가하여 0-10℃ 냉장고에서 24시간 방치한다.The filtrate was concentrated under reduced pressure, and excess water-soluble alcohol (meaning C1-C5 aliphatic alcohol such as methanol, ethanol, butanol) was added thereto, and the mixture was left to stand in a 0-10 ° C refrigerator for 24 hours.
이때 많은 양의 침전물이 생긴다. 이 침전물을 걸러서 동결건조하면 인진쑥 단백 다당체를 얻을 수 있다.At this time, a large amount of precipitate is formed. Filtering this precipitate and freeze-drying can yield the Injin mugwort protein polysaccharide.
간기능 개선에 우수한 활성을 갖는 인진쑥 단백 다당체의 분획을 알아내기 위한 정제법은 다음과 같다.The purification method for determining the fraction of the phospholipid protein polysaccharide having excellent activity in improving liver function is as follows.
인진쑥 단백 다당체를 물에 녹인후 세파덱스(Sephadex), 로즈(Sepharose), 세파크릴(Sephacryl) 등으로 충진된 컬럼에 통과시키거나 또는 한외여과용막을 통과시켜 분획을 받는다.Phosphorus wormwood protein polysaccharide is dissolved in water and passed through a column filled with Sephadex, Rose, Sephacryl, etc., or passed through an ultrafiltration membrane to receive a fraction.
각 분획을 파장 200-800nm에서 자외-가시 스펙트럼을 얻어 흡광도가 큰 분획을 선별하여 최종분획(KP)으로 취한다.Each fraction is obtained by ultraviolet-visible spectrum at a wavelength of 200-800 nm, and fractions having high absorbance are selected and taken as final fractions (KP).
이 KP를 동결건조시킨다.Lyophilize this KP.
이 KP는 간세포 부활 능력과 간염에 대한 치료효과가 매우 대단히 우수하다. 다음에 실시예 및 실험예로서 본 발명을 더욱 상세히 설명한다.This KP has a very good ability to rejuvenate hepatocytes and to cure hepatitis. Next, the present invention will be described in more detail as Examples and Experimental Examples.
[실시예 1]Example 1
인진쑥 200gr을 곱게 세절한 후 pH가 4로 조정된 45-55℃의 인산수용액으로 9시간 2회 추출한다.Finely grind 200 gr of phosphorus mugwort and extract twice with 9 hours with an aqueous solution of 45-55 ° C. adjusted to pH 4.
여과한 후 여과액을 완전 감압농축하고 동결건조하니 50.2gr의 엑스를 얻을 수 있다.After filtration, the filtrate was concentrated under reduced pressure and lyophilized to obtain 50.2 gr of X.
이 엑스를 120ml의 물에 녹인 후 황산암모늄 20gr을 가하고 에탄올 500ml를 가하여 5℃의 냉장고에서 24시간 방치하면 침전물인 인진쑥 단백 다당체를 5.0gr 얻을 수 있다.After dissolving the extract in 120 ml of water, 20 gr of ammonium sulfate was added and 500 ml of ethanol was added and left in a refrigerator at 5 ° C. for 24 hours to obtain 5.0 gr of phosphorus polysaccharide, a precipitate.
인진쑥 단백 다당체를 여과한 후 세파덱스 G 200이 충진된 컬럼에서 5ml씩 분획을 받아 각각을 파장이 400nm에서 자외-가시 스펙트럼을 얻어 흡광도가 1.0 이상인 분획을 주분획으로 하였다.After filtering the phospholipid protein polysaccharide, 5 ml fractions were collected from the column packed with Sephadex G 200, and the ultraviolet-visible spectrum was obtained at a wavelength of 400 nm, respectively.
이 주분획을 -40℃에서 20시간, -30℃에서 10시간, -20℃에서 5시간, -10℃에서 3시간, 0℃에서 1시간 동결건조하면 최종분획인 KP가 얻어진다.The main fraction was lyophilized for 20 hours at -40 ° C, 10 hours at -30 ° C, 5 hours at -20 ° C, 3 hours at -10 ° C, and 1 hour at 0 ° C to obtain the final fraction, KP.
KP를 가수분해한후 HPLC를 이용하여 구성당을 측정한 결과 글루코오스(glucose) 71.2%, 자일로오스(xylose) 25.4%, 만노오스(mannose) 2.8%, 람노오스(rhamnose) 0.6%인 것으로 측정되었다.After hydrolysis of KP, constituent sugars were measured by HPLC, and the results were 71.2% glucose, 25.4% xylose, 2.8% mannose, and 0.6% rhamnose. .
KP의 원소분석결과를 보면 질소가 1.4% 함유되어 있으며 이는 KP에는 아미노산이 포함되어 있는 단백 다당체임을 시사한다.Elemental analysis of KP contains 1.4% nitrogen, suggesting that KP is a protein polysaccharide with amino acids.
[실험예 1]Experimental Example 1
[GOP 및 GPT의 측정][Measurement of GOP and GPT]
KP의 간세포 재생 능력을 알아보기 위하여 다음과 같은 동물 실험을 하였다.The following animal experiments were conducted to determine KP's hepatocyte regeneration ability.
실험동물로는 체중 200gr 내외의 Sprague-Dawley계 rat를 항온, 항습이 유지되는 동물사육실에서 일주일 이상 적응시킨 후 일반상태를 관찰하여 외관상 건강한 동물을 선별하여 실험에 사용하였다.As experimental animals, Sprague-Dawley rats with a body weight of about 200 gr were acclimated for at least one week in an animal breeding room maintained at constant temperature and humidity.
실험방법은 다음과 같다.The experimental method is as follows.
위 rat에 CCl4와 corn oil의 혼합액(1:9v/v%)을 체중 100gr당 0.2ml씩 복강내 투여하고 48시간 후에 ether 마취하에 개복하여 복부 대동맥에서 체혈하여 원심분리한 후 상등액을 취하여 GOT, GPT 활성을 측정하였다.CCl 4 and corn oil mixed solution (1: 9v / v%) was intraperitoneally administered 0.2ml per 100gr body weight, and then 48 hours later, under anesthesia with ether, the body was circulated in the abdominal aorta and centrifuged. , GPT activity was measured.
약물 처치군의 각 약물은 PVP와 tween 80을 섞은 0.5% CMC 용액에 현탁시켜 CCl4투여전 24시간 및 CCl4투여 2시간 후 및 24시간 후에 각 3회 경구투여하였다.Each dose of the drug treatment group was administered 0.5% CMC solution, and suspended in a mixture of PVP and tween 80 CCl 4 CCl 4 and administered 24 hours before administration After 2 hours and 24 hours after each of 3 single oral.
실험결과는 다음과 같다.The experimental results are as follows.
정상조건하에서 흰쥐의 혈액내 GOT, GPT치는 각각 60±6U/L, 25±2U/L이었으나 CCl를 투여한 대조군의 경우 GOT치는 1207±139U/L이었고, GPT치 역시 731±133U/L로 증가하였다.Under normal conditions, GOT and GPT levels in rats were 60 ± 6U / L and 25 ± 2U / L, respectively, but the GOT value was 1207 ± 139U / L in the CCl-treated control group and the GPT value was increased to 731 ± 133U / L, respectively. It was.
그러나 KP로 3회 처치한 군의 경우 GOT치는 206±97U/L로 매우 감소함을 알 수 있었다.However, in the group treated with KP three times, the GOT value was found to be greatly reduced to 206 ± 97U / L.
따라서 세파덱스로 정제한 인진쑥 단백 다당체 분획인 KP는 강력한 간세포 재생 능력이 있는 것으로 판단된다.Therefore, KP, a fraction of the Artemisia erythrocyte protein polysaccharide, purified by Sephadex, is considered to have strong hepatocyte regeneration ability.
[실험예 2]Experimental Example 2
[AST 및 ALT의 측정][Measurement of AST and ALT]
실험동물로는 체중 200gr 내외의 Sprague-Dawley계 rat를 항온, 항습이 유지되는 동물사육실에서 일주일 이상 적응시킨 후 일반상태를 관찰하여 외관상 건강한 동물을 선별하여 실험에 사용하였다.As experimental animals, Sprague-Dawley rats with a body weight of about 200 gr were acclimated for at least one week in an animal breeding room maintained at constant temperature and humidity.
실험방법은 다음과 같다.The experimental method is as follows.
위 rat에 galactosamine(sigma chemical co., USA)를 체중 100gr당 0.2ml(800mg/kg)씩 복강내 투여하고 48시간 후에 ether 마취하에 개복하여 복부 대동맥에서 채혈하여 원심분리한 후 상등액을 취하여 AST, ALT 활성을 측정하였다.Galactosamine (sigma chemical co., USA) was intraperitoneally administered 0.2ml (800mg / kg) per 100gr body weight in the rat, and 48 hours later, it was opened under ether anesthesia, collected in the abdominal aorta, and centrifuged. ALT activity was measured.
약물 처치군의 각 약물은 PVP와 tween 80을 섞은 0.5% CMC 용액에 현탁시켜 galactosamine 투여 3일전부터 1일 1회 경구투여하였다.Each drug in the treatment group was suspended orally in a 0.5% CMC solution containing PVP and tween 80 once a day from 3 days before galactosamine administration.
실험결과는 다음과 같다.The experimental results are as follows.
정상조건하에서 흰쥐의 혈액내 AST, ALT치는 각각 60±6U/L, 25±2U/L이었으나 galactosamine을 투여한 대조군의 경우 AST치는 2655.8±144.7U/L이었고, ALT치 역시 1935.1±128.6U/L로 증가하였다.Under normal conditions, AST and ALT levels in rats were 60 ± 6U / L and 25 ± 2U / L, respectively, but AST was 2655.8 ± 144.7U / L for galactosamine-treated control group, and ALT was 1935.1 ± 128.6U / L, respectively. Increased to.
그러나 KP로 3회 처치한 군의 경우 AST치는 1137.6±192.1U/L, ALT치는 742.8±97.4U/L로 매우 감소함을 알 수 있었다.However, in the group treated with KP three times, the AST value was significantly decreased to 1137.6 ± 192.1U / L and ALT to 742.8 ± 97.4U / L.
따라서 세파덱스로 정제한 인진쑥의 단백 다당체 분획인 KP는 강력한 급성 간염 치료효과가 있는 것으로 판단된다.Therefore, KP, a protein polysaccharide fraction of Injin mugwort purified with Sephadex, seems to have a strong acute hepatitis treatment effect.
[실험예 3]Experimental Example 3
KP의 자외-가시 분광 스펙트럼은 제1도, 적외선 분광 스펙트럼은 제2도에 나타내었다.The ultraviolet-visible spectral spectrum of KP is shown in FIG. 1, and the infrared spectral spectrum is shown in FIG.
KP의 아미노산 정성, 정량은 아미노산 자동분석기를 이용하여 분석하였다.Amino acid qualitative and quantitative analysis of KP was carried out using an amino acid autoanalyzer.
분석결과는 다음의 표와 같다.The analysis results are shown in the following table.
아미노산 분석 크로마토그램은 제3도에 나타내었다.Amino acid analysis chromatogram is shown in FIG.
또한, KP의 원소분석 결과 탄소:수소:질소가 각각 34.2:3.7:1.4의 비율로 구성되어 있다.In addition, elemental analysis of KP shows that carbon: hydrogen: nitrogen is composed of 34.2: 3.7: 1.4 ratio, respectively.
이상의 실험결과에서 확인되는 바와 같이, 본 발명의 인진쑥 다당체는 간세포보호 기능이 탁월함을 알 수 있다.As confirmed in the above experimental results, it can be seen that the erythroid polysaccharide of the present invention has an excellent hepatoprotective function.
지금까지의 연구로서는 인진쑥에서 간기능 개선효과를 나타내는 물질이 유기용매로 추출하였을때, 저분자물질인 capillarisin, scoparone 등으로 알려져 있으나, 본 발명의 결과 capillarisin, scoparone이 많이 함유된 유기층의 저분자 물질보다 수층으로 이행된 고분자 물질인 인진쑥 단백 다당체가 더욱 우수한 간기능 개선효과가 나타났다.Until now, it is known that capillarisin and scoparone, which are low molecular materials, are extracted from organic solvents when the substances that improve liver function in jinjin mugwort have been extracted with organic solvents. Phosphorus mugwort protein polysaccharide, a high-molecular substance, was found to improve liver function.
[실험예 4]Experimental Example 4
[급성독성실험][Acute Toxicity Test]
인진쑥은 오래전부터 식용으로 상용하여 왔으며, 체중 200gr의 Sprague-Dawley계 랫트에 체중 Kg당 단백 다당체 2gr을 경구투여하였으나 사망예는 없었다. 따라서 인진쑥 다당체는 독성이 없는 것으로 판단된다.Injin mugwort has been commercially available for a long time, and 2 g of protein polysaccharide per Kg was orally administered to Sprague-Dawley rats weighing 200 gr. Therefore, it is considered that Injin mugwort polysaccharide is not toxic.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950023493A KR0155231B1 (en) | 1995-07-31 | 1995-07-31 | Proteoglycan extracted from artemisza swa yomogi and their preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950023493A KR0155231B1 (en) | 1995-07-31 | 1995-07-31 | Proteoglycan extracted from artemisza swa yomogi and their preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970005303A KR970005303A (en) | 1997-02-19 |
KR0155231B1 true KR0155231B1 (en) | 1998-11-16 |
Family
ID=19422446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950023493A KR0155231B1 (en) | 1995-07-31 | 1995-07-31 | Proteoglycan extracted from artemisza swa yomogi and their preparation method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR0155231B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100420767B1 (en) * | 2002-01-31 | 2004-03-02 | 현 용 이 | The preparing method of the ingin-mugwort extract in which the components of bitter taste were selectively removed, and the functional liquid food of using it |
-
1995
- 1995-07-31 KR KR1019950023493A patent/KR0155231B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100420767B1 (en) * | 2002-01-31 | 2004-03-02 | 현 용 이 | The preparing method of the ingin-mugwort extract in which the components of bitter taste were selectively removed, and the functional liquid food of using it |
Also Published As
Publication number | Publication date |
---|---|
KR970005303A (en) | 1997-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5032580A (en) | Compositions for activirus medicines | |
US4948785A (en) | Plant polysaccharide fractions inducing prolactin in mammals | |
JPH05504937A (en) | Compositions based on proanthocyanidol. Its pharmacological application | |
CN115154476B (en) | Cyclocarya paliurus extract and application thereof in resisting gout and reducing uric acid | |
US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
CN103804443A (en) | Flavonoid glycoside compound and preparation method thereof | |
US4537774A (en) | Hot-water extracts of neem bark | |
US5484595A (en) | Process for preparation of dibenzocyclooctadiene type lignan | |
US5422393A (en) | Natriuretic hormone | |
KR0155231B1 (en) | Proteoglycan extracted from artemisza swa yomogi and their preparation method | |
KR100210414B1 (en) | Amino acid containing polysaccharide of artemisia iwayomigi and its purification method | |
Cubukcu et al. | Constituents of Anatolian medicinal plants; flavonoids of Helichrysum armenium | |
JP4480204B2 (en) | Anti-tumor fraction of Kawariharatake | |
EP0429480B1 (en) | Natriuretic hormone | |
Asres et al. | Studies on the anti-inflammatory activity of extracts and compounds from the leaves of Melilotus elegans | |
CN105541932A (en) | Phenethyl alcohol glycoside compound extracted from common cephalanoplos herb and application | |
US3832343A (en) | Process for obtaining an extract of arnica montana | |
JP2003221333A (en) | Agent for inhibiting hyaluronidase | |
KR100200182B1 (en) | Composition having liver-protecting effect, which contains isoflavone isolated from astragalus membranaceus | |
JP2521083B2 (en) | Polysaccharides having heparinoid activity, method for producing the same, and anticoagulant containing the same | |
CN115806490B (en) | Phenolic hetero-terpene compound with function of activating AMPK phosphorylation, pharmaceutical composition, preparation method and application | |
US5106630A (en) | Natriuretic hormone | |
CN110498863A (en) | Climbing fig leaf polyose and preparation method thereof and preparing the purposes in anticomplement medicament | |
JPS60184025A (en) | Polysaccharide, separation and use thereof | |
CN116509921A (en) | Application of rice flower sesterterpene extract K01 in preparation of medicines for treating sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20040624 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |